

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GENERIC
PHARMACEUTICALS PRICING
ANTITRUST LITIGATION**

IN RE: CLOMIPRAMINE CASES

**THIS DOCUMENT APPLIES TO:
*DPP BELLWETHER ACTIONS***

**MDL NO. 2724
16-md-2724**

DPP CASE: 16-CM-27241

DPP CASE: 16-CM-27242

ORDER

AND NOW, this 27th day of August 2025, upon consideration of Defendants’ Motions for Summary Judgment in the Direct Purchaser Plaintiffs’ (“DPPs”) and End Payer Plaintiffs’ (“EPPs”) clomipramine cases [16-CM-27241: Doc. No. 148, and 16-CB-27242: Doc Nos. 293, 295, 297] and the responses and replies therefore, and after hearings and arguments held on May 13-14, 2025, and for the reasons set forth in the accompanying Opinion, it is hereby **ORDERED** that:

- Mylan’s motion for summary judgment in the DPPs’ case is **DENIED**.
- Defendants’ joint motion for summary judgment in the EPPs’ case is **DENIED** in part and **GRANTED** in part as to the consumer protection claims arising from state law in Missouri and Minnesota.
- Mylan’s motion for summary judgment in the EPPs’ case is **DENIED** in part and **GRANTED** in part as to EPPs’ claims arising from sales of clomipramine from Mylan to CVS pharmacy.
- Tar and Sandoz’s joint motion for summary judgment is **DISMISSED** without prejudice, pending the outcome of each party’s settlement agreements with EPPs.

It is further **ORDERED** that the Motions to Seal [16-CM-27241: Doc. No. 189 and 16-CB-27242: Doc. No. 381] are **GRANTED**.

It is so **ORDERED**.

BY THE COURT:

/s/ Cynthia M. Rufe
CYNTHIA M. RUFÉ, J.